Atorvastatin plus omega-3 fatty acid ethyl ester decreases very-low-density lipoprotein triglyceride production in insulin resistant obese men

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aim

To test the effect of atorvastatin (ATV) and ATV plus ω-3 FAEEs on VLDL-TG metabolism in obese, insulin resistant men.

Methods

We carried out a 6-week randomized, placebo-controlled study to examine the effect of ATV (40 mg/day) and ATV plus ω-3 FAEEs (4 g/day) on VLDL-TG metabolism in 36 insulin resistant obese men. VLDL-TG kinetics were determined using d5-glycerol, gas chromatography–mass spectrometry and compartmental modelling.

Results

Compared with the placebo, ATV significantly decreased VLDL-TG concentration (−40%, p < 0.001) by increasing VLDL-TG fractional catabolic rate (FCR) (+47%, p < 0.01). ATV plus ω-3 FAEEs lowered VLDL-TG concentration to a greater degree compared with placebo (−46%, p < 0.001) or ATV monotherapy (−13%, p = 0.04). This was achieved by a reduction in VLDL-TG production rate (PR) compared with placebo (−32%, p = 0.008) or ATV (−20%, p = 0.03) as well as a reciprocal increase in VLDL-TG FCR (+42%, p < 0.05) compared with placebo.

Conclusion

In insulin resistant, dyslipidaemic, obese men, ATV improves VLDL-TG metabolism by increasing VLDL-TG FCR. The addition of 4 g/day ω-3 FAEE to statin therapy provides further TG-lowering by lowering VLDL-TG PR.

Original languageEnglish
Pages (from-to)519-526
JournalDiabetes, Obesity and Metabolism
Volume16
Issue number6
DOIs
Publication statusPublished - Jun 2014

Fingerprint

Omega-3 Fatty Acids
Esters
Insulin
Placebos
very low density lipoprotein triglyceride
Atorvastatin Calcium
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Glycerol
Spectrum Analysis
Gases

Cite this

@article{0fa74697d9244c9f8c6ca8803a218138,
title = "Atorvastatin plus omega-3 fatty acid ethyl ester decreases very-low-density lipoprotein triglyceride production in insulin resistant obese men",
abstract = "Aim To test the effect of atorvastatin (ATV) and ATV plus ω-3 FAEEs on VLDL-TG metabolism in obese, insulin resistant men. Methods We carried out a 6-week randomized, placebo-controlled study to examine the effect of ATV (40 mg/day) and ATV plus ω-3 FAEEs (4 g/day) on VLDL-TG metabolism in 36 insulin resistant obese men. VLDL-TG kinetics were determined using d5-glycerol, gas chromatography–mass spectrometry and compartmental modelling. Results Compared with the placebo, ATV significantly decreased VLDL-TG concentration (−40{\%}, p < 0.001) by increasing VLDL-TG fractional catabolic rate (FCR) (+47{\%}, p < 0.01). ATV plus ω-3 FAEEs lowered VLDL-TG concentration to a greater degree compared with placebo (−46{\%}, p < 0.001) or ATV monotherapy (−13{\%}, p = 0.04). This was achieved by a reduction in VLDL-TG production rate (PR) compared with placebo (−32{\%}, p = 0.008) or ATV (−20{\%}, p = 0.03) as well as a reciprocal increase in VLDL-TG FCR (+42{\%}, p < 0.05) compared with placebo. Conclusion In insulin resistant, dyslipidaemic, obese men, ATV improves VLDL-TG metabolism by increasing VLDL-TG FCR. The addition of 4 g/day ω-3 FAEE to statin therapy provides further TG-lowering by lowering VLDL-TG PR.",
author = "Ng, {Theodore Wai} and Esther Ooi and Gerald Watts and Dick Chan and Hugh Barrett",
year = "2014",
month = "6",
doi = "10.1111/dom.12243",
language = "English",
volume = "16",
pages = "519--526",
journal = "Diabets, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Atorvastatin plus omega-3 fatty acid ethyl ester decreases very-low-density lipoprotein triglyceride production in insulin resistant obese men

AU - Ng, Theodore Wai

AU - Ooi, Esther

AU - Watts, Gerald

AU - Chan, Dick

AU - Barrett, Hugh

PY - 2014/6

Y1 - 2014/6

N2 - Aim To test the effect of atorvastatin (ATV) and ATV plus ω-3 FAEEs on VLDL-TG metabolism in obese, insulin resistant men. Methods We carried out a 6-week randomized, placebo-controlled study to examine the effect of ATV (40 mg/day) and ATV plus ω-3 FAEEs (4 g/day) on VLDL-TG metabolism in 36 insulin resistant obese men. VLDL-TG kinetics were determined using d5-glycerol, gas chromatography–mass spectrometry and compartmental modelling. Results Compared with the placebo, ATV significantly decreased VLDL-TG concentration (−40%, p < 0.001) by increasing VLDL-TG fractional catabolic rate (FCR) (+47%, p < 0.01). ATV plus ω-3 FAEEs lowered VLDL-TG concentration to a greater degree compared with placebo (−46%, p < 0.001) or ATV monotherapy (−13%, p = 0.04). This was achieved by a reduction in VLDL-TG production rate (PR) compared with placebo (−32%, p = 0.008) or ATV (−20%, p = 0.03) as well as a reciprocal increase in VLDL-TG FCR (+42%, p < 0.05) compared with placebo. Conclusion In insulin resistant, dyslipidaemic, obese men, ATV improves VLDL-TG metabolism by increasing VLDL-TG FCR. The addition of 4 g/day ω-3 FAEE to statin therapy provides further TG-lowering by lowering VLDL-TG PR.

AB - Aim To test the effect of atorvastatin (ATV) and ATV plus ω-3 FAEEs on VLDL-TG metabolism in obese, insulin resistant men. Methods We carried out a 6-week randomized, placebo-controlled study to examine the effect of ATV (40 mg/day) and ATV plus ω-3 FAEEs (4 g/day) on VLDL-TG metabolism in 36 insulin resistant obese men. VLDL-TG kinetics were determined using d5-glycerol, gas chromatography–mass spectrometry and compartmental modelling. Results Compared with the placebo, ATV significantly decreased VLDL-TG concentration (−40%, p < 0.001) by increasing VLDL-TG fractional catabolic rate (FCR) (+47%, p < 0.01). ATV plus ω-3 FAEEs lowered VLDL-TG concentration to a greater degree compared with placebo (−46%, p < 0.001) or ATV monotherapy (−13%, p = 0.04). This was achieved by a reduction in VLDL-TG production rate (PR) compared with placebo (−32%, p = 0.008) or ATV (−20%, p = 0.03) as well as a reciprocal increase in VLDL-TG FCR (+42%, p < 0.05) compared with placebo. Conclusion In insulin resistant, dyslipidaemic, obese men, ATV improves VLDL-TG metabolism by increasing VLDL-TG FCR. The addition of 4 g/day ω-3 FAEE to statin therapy provides further TG-lowering by lowering VLDL-TG PR.

U2 - 10.1111/dom.12243

DO - 10.1111/dom.12243

M3 - Article

VL - 16

SP - 519

EP - 526

JO - Diabets, Obesity and Metabolism

JF - Diabets, Obesity and Metabolism

SN - 1462-8902

IS - 6

ER -